Jan 21 2021 Read 877 Times
Thermo Fisher Scientific Inc and Groupe Novasep SAS have announced that Thermo Fisher has completed the acquisition of Henogen SA, Novasep’s viral vector manufacturing business in Belgium for approximately €725 million in cash.
Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, Belgium, Novasep’s viral vector business offers more than 7,000 m2 of state-of-the-art clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of €80 million (or approximately $95 million).
Thermo Fisher Scientific acquires Novasep's viral vector manufacturing business for €725 million zenopa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zenopa.com Daily Mail and Mail on Sunday newspapers.
Thermo Fisher Scientific announced the acquisition of Henogen, a Belgian viral vector manufacturing business belonging to Groupe Novasep, for about $875m.